For the Inventor, By the Inventor

Enter assignee name

Montreal, Canada

Supratek Pharma Inc.

Calculating rank

USPTO Granted Patents = 30

% Expired Patents = 33.3

CIPO Patents = 1

EPO Patents = 4

Forward Citations = 660

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Valery Yu Alakhov (19 out of 23 patents)

Alexander Victorovich Kabanov (18 out of 36 patents)

Grzegorz Pietrzynski (8 out of 10 patents)

4. Sergey V Vinogradov (4 out of 5 patents)

5. Valery Yulievich Alakov (4 out of 4 patents)

6. Elena V Batrakova (3 out of 7 patents)

7. Kishore Patel (3 out of 6 patents)

8. Lioudmila Tchistiakova (3 out of 3 patents)

9. Shengmin Li (3 out of 3 patents)

10. Pierre M Lemieux (3 out of 3 patents)

11. Tomasz Popek (2 out of 2 patents)

12. Patel Kishore (2 out of 2 patents)

13. Thomasz Popek (2 out of 2 patents)

14. Evgueni Klinski (2 out of 2 patents)

15. Serguei V Vinogradov (2 out of 6 patents)

Core Competencies:

Bendamustine

Polynucleotide Compositions

Nanogel Networks

Dendritic Cells

Chemotherapeutic Compositions

Vascular Endothelial Growth Factor

Amphiphilic Compositions

Copolymer Compositions

Biological Agents

Oral Delivery

Tumor Treatment

30 patents: Sort by Forward Citations

1. 8703964 - Bendamustine cyclopolysaccharide compositions (2014-04-22),

2. 8436032 - Bendamustine cyclopolysaccharide compositions (2013-05-07),

3. 8389558 - Bendamustine amphiphilic anionic compositions (2013-03-05),

4. 8383663 - Bendamustine anionic-catioinic cyclopolysaccharide compositions (2013-02-26),

5. 8148338 - Doxorubicin formulations for anti-cancer use (2012-04-03),

6. 7772255 - Method of treating tumors with azaxanthones (2010-08-10),

7. 7256180 - Compositions and methods for inducing activation of dendritic cells (2007-08-14),

8. 7204997 - Responsive microgel and methods related thereto (2007-04-17),

9. 7112654 - Ligand for vascular endothelial growth factor receptor (2006-09-26),

10. 6733755 - Ligand for vascular endothelial growth factor receptor (2004-05-11),

11. 6696274 - Ligand for enhancing oral and CNS delivery of biological agents (2004-02-24),

12. 6656459 - Compositions of non-ionic block copolymers to treat autoimmune and inflammatory diseases, and to reduce graft/implantation, and methods of use thereof (2003-12-02),

13. 6440743 - Methods of using polynucleotide compositions (2002-08-27),

14. 6387633 - Method for identifying unstable genes (2002-05-14),

15. 6387406 - Copolymer compositions for oral delivery (2002-05-14),

Company Overview

Supratek Pharma Inc. is a biopharmaceutical company based in Montreal, Canada, focused on the development of innovative therapies for cancer treatment. The organization specializes in the research and manufacturing of targeted therapies that aim to improve patient outcomes through precision medicine. With a commitment to advancing healthcare, Supratek Pharma leverages cutting-edge technology and scientific expertise to address unmet medical needs in oncology, striving to enhance the quality of life for patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

30 Patents

#34 in Montreal

#463 in Canada

#21,924 in the World

Montreal, Canada

Supratek Pharma Inc.

Forward Citations = 660

30 inventors:

Valery Yu Alakhov (19 out of 23 patents)

Alexander Victorovich Kabanov (18 out of 36 patents)

Grzegorz Pietrzynski (8 out of 10 patents)

4. Sergey V Vinogradov (4 out of 5 patents)

5. Valery Yulievich Alakov (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Supratek Pharma Inc.. Retrieved from https://idiyas.com/company/supratek-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…